Page last updated: 2024-10-28

hydroxyurea and Tetralogy of Fallot

hydroxyurea has been researched along with Tetralogy of Fallot in 1 studies

Tetralogy of Fallot: A combination of congenital heart defects consisting of four key features including VENTRICULAR SEPTAL DEFECTS; PULMONARY STENOSIS; RIGHT VENTRICULAR HYPERTROPHY; and a dextro-positioned AORTA. In this condition, blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into the body often causing CYANOSIS.

Research Excerpts

ExcerptRelevanceReference
"Hydroxyurea seems to be an eddicient there alternative therapy for seconday polycythemia caused by incurable cyantic congenital heart disease."1.34[Chemotherapy against polycythemia due to a cyanotic congenital heart disease in adults. One case report]. ( Békir, S; Ben Romdhane, N; Boussaada, R; Mechmèche, R, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boussaada, R1
Békir, S1
Ben Romdhane, N1
Mechmèche, R1

Other Studies

1 other study available for hydroxyurea and Tetralogy of Fallot

ArticleYear
[Chemotherapy against polycythemia due to a cyanotic congenital heart disease in adults. One case report].
    La Tunisie medicale, 2007, Volume: 85, Issue:5

    Topics: Adult; Erythrocytes; Follow-Up Studies; Heart Defects, Congenital; Heart Septal Defects, Ventricular

2007